IBRX – immunitybio, inc. (US:NASDAQ)
Stock Stats
News
ImmunityBio, Inc. (NASDAQ: IBRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
ImmunityBio, Inc. (NASDAQ: IBRX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $30.00 price target on the stock.
ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia [Yahoo! Finance]
ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia
ImmunityBio, Inc. (NASDAQ: IBRX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $30.00 price target on the stock.
Form 8-K ImmunityBio, Inc. For: Apr 15
Form 424B5 ImmunityBio, Inc.
Form 8-K ImmunityBio, Inc. For: Apr 07
Form 8-K ImmunityBio, Inc. For: Mar 13
Form 10-K ImmunityBio, Inc. For: Dec 31
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.